Role of clinical and laboratory parameters for treatment choice in patients with inherited FVII deficiency undergoing surgical procedures: evidence from the STER registry

Perioperative bleeding is a major concern in patients with factor VII (FVII) deficiency. Evaluating data of 95 FVII-deficient patients undergoing 110 surgical procedures (61 major, 49 minor), we assessed the impact of type of surgery, bleeding phenotype and FVII coagulant activity (FVII:C) levels on perioperative replacement therapy (RT). Compared to those with higher FVII:C levels, patients with <3% FVII:C received a higher number of RT doses (8 vs. 2, P = 0.003) for a longer RT duration (3 days vs. 1 day, P = 0.001), with no difference in RT dose. Similarly, patients with a history of major bleeds received a higher number of RT doses (8.5 vs. 2-3, P = 0.013) for a longer RT duration (2 days vs. 1 day, P = 0.005) as compared to those with a history of minor bleeds or to asymptomatic patients. No difference in RT was found among major and minor surgical procedures. Overall, multivariate analysis showed that history of major bleeding was the only independent predictor of number of RT doses (beta = 0.352, P = 0.001) and RT duration (beta = 0.405, P = 0.018). Overall, a approximate to 20 mu g/kg perioperative RT was efficacious in 95.5% of cases. The infusion should be repeated approximate to 8 times in high-risk subsets (i.e. patients with a history of major bleeding).